1) RhoA kinase
RhoA激酶
1.
Simvastatin prevents rat cardiac hypertrophy induced by myocardial infarction via RhoA kinase
辛伐他汀抑制心肌梗死后大鼠心肌细胞肥大与RhoA激酶关系
2) RhoA/Rho-kinase
RhoA/Rho激酶
1.
Relationship Between RhoA/Rho-kinase Singaling Pathway and Penile Erection;
RhoA/Rho激酶信号通路与阴茎勃起功能关系
2.
Effects of RhoA/Rho-kinase in the Regulation of Penile Erection;
RhoA/Rho激酶在阴茎勃起中的作用
3) RhoA/Rho kinase
RhoA/Rho激酶
1.
RhoA/Rho kinase:a potential new target for drug therapy in asthma and development of inhibitors
哮喘治疗新靶点——RhoA/Rho激酶及其抑制剂开发
2.
It has shown that vasoconstriction in the cavernosal circulation is mediated by the RhoA/Rho kinase calcium sensitization pathway.
阴茎海绵体血管的收缩及张力的维持是由钙敏感的RhoA/Rho激酶信号传导途径介导的。
3.
Objective:To investigate the role of RhoA/Rho kinase system in the onset of labor.
目的:探讨子宫平滑肌组织RhoA/Rho激酶信号传导通路的表达变化在分娩发动中的作用。
5) kinase
[英]['kineis] [美]['kaɪ,nes, -,nez, 'kɪn,es, ,ez]
激酶
1.
[Objective] The inhibitory effect of indirubin on cell growth was studied in some human tumor cell lines relating with cyclin-dependent kinases(CDK) or Src kinase.
[目的]探讨靛玉红对与细胞周期依赖性蛋白激酶(CDK)、Src激酶有关的人类肿瘤细胞生长的抑制作用。
2.
Purpose:To invastigate the changes of the related signaling pathways and it s mechanism of reguation of mitogen activated protein kinase cascade(MAPK) by SUM149 cells induced plasmid of dominant-negative E-cadherin mutant H-2k~d-E-cadherin.
1(-)H-2kd-E-cadherin)导入SUM149细胞系后,对丝裂原活化蛋白激酶信号传导系统(mitogenactivatedproteinkinasecascade,MAPK)的相关信号通路及调控机制的改变情况。
3.
Besides inhibiting protein Kinase C very well, they show potential bioactivities against Cyclin dependent kinase and Checkpoint kinase, and cell proliferation.
此类化合物对蛋白激酶C、细胞周期蛋白依赖激酶、检测点激酶等都具有较好的抑制作用 ,并能抑制肿瘤细胞增殖 ,因此可用于肿瘤的治
6) MAPK kinase kinase
MAPK激酶激酶
1.
The conserved MAPK module includes three kinases that establish a sequential activation pathway comprising a MAPK, MAPK kinase ( MKK) and MAPK kinase kinase (MKKK).
MAPK途径的基本组合包括MAPK、MAPK激酶(MKK)和MAPK激酶激酶(MKKK)三种保守的成分,由此建立一个连续的激活途径。
补充资料：[3-(aminosulfonyl)-4-chloro-N-(2.3-dihydro-2-methyl-1H-indol-1-yl)benzamide]
分子式：C16H16ClN3O3S
分子量：365.5
CAS号：26807-65-8
性质：暂无
制备方法：暂无
用途：用于轻、中度原发性高血压。
分子量：365.5
CAS号：26807-65-8
性质：暂无
制备方法：暂无
用途：用于轻、中度原发性高血压。
说明：补充资料仅用于学习参考，请勿用于其它任何用途。
参考词条